Dreux

Researchers are studying patients with community-acquired pneumonia who need oxygen therapy due to acute respiratory distress and low blood oxygen levels. This research aims to see if placing patients in a prone position lying face down while they receive nasal high flow oxygen can reduce the need for intubation and improve outcomes. The study particularly excludes patients with COVID-19 and focuses on non-COVID pneumonia cases. Participants will be randomly assigned to one of two groups. One group will be encouraged and assisted to lie in the prone position for at least 8 hours per day in multiple sessions, aiming for up to 16 hours if tolerated. The other group will receive usual care with nasal high flow oxygen therapy but no prone positioning. Both groups will have oxygen levels monitored and care adjusted to maintain target oxygen saturation. During the study, patients will be observed for intubation rates within 28 days, comfort levels during prone positioning, oxygenation changes, time to escalation of breathing support, and overall outcomes including mortality up to 90 days. Safety measures like skin and infection monitoring will also be recorded. Quality of life will be assessed at 90 days and 5 years, with nursing workload tracked within the first day after randomization.

Schizophrenia, affecting about 0.7 of the population, often leads to poor insight and medication compliance, resulting in relapses and a reduced quality of life. Researchers are evaluating an individual early psychoeducation program called PEPITS for inpatients with schizophrenia or related disorders. The study aims to see if PEPITS can reduce relapses, improve medication adherence and insight, and enhance quality of life. The PEPITS program is delivered by nurses during the initial hospitalization phase and consists of three parts an introduction session, sessions focused on understanding the illness and care, and sessions on recovery and building coping skills. Participants are randomly assigned to either the PEPITS program or to usual psychiatric care without PEPITS. Participants will be monitored from the start of the study until one year after randomization to assess changes in insight, quality of life, and medication compliance. Additional evaluations include quality of life and psychological well-being at work, job satisfaction, self-efficacy, and work commitment over six months. The study involves regular assessments to track these outcomes and better understand the programs impact.

Researchers are exploring the effects of continuing oral intake versus fasting in adult patients with acute respiratory failure in intensive care units who are not intubated. This trial aims to evaluate whether allowing patients to eat and drink before potential intubation affects the risk of intubation or aspiration-related complications. The study addresses a gap in knowledge as current guidelines lack data on nutritional management for these patients despite common fasting practices and frequent nutritional deficits. Participants are randomly assigned to one of two groups one group continues oral intake of liquids and solid foods without restrictions, supported by nursing assistance and regular oral care, while the other group follows a fasting protocol with no ingestion of food or liquids except minimal water for essential oral medications if needed. Both groups receive intravenous glucose or parenteral nutrition as necessary, and caloric intake is monitored. The study includes a 96-hour primary observation period after randomization. During the study, participants undergo assessments of respiratory status, nutritional intake, and discomfort levels such as thirst and hunger using verbal scales. Researchers monitor intubation rates, mortality, episodes of vomiting during intubation, salivary enzyme levels, and occurrences of pneumonia, renal failure, and hypoglycemia up to 28 days. The trial also tracks electrolyte levels and adverse events, with regular follow-up to evaluate safety and clinical outcomes over time.

Researchers are conducting an ambispective, observational, multicenter, and multicohort study focusing on patients with non-small cell lung cancer NSCLC who are starting treatments with approved drugs developed by AstraZeneca or its alliance partners. The study includes three groups based on the stage of NSCLC resectable, unresectable, and metastatic. This modular study is designed to evaluate patients receiving these drugs once they have European marketing authorization and are available in the participating countries. Patients will be observed whether they have already received, are currently receiving, or will receive approved AstraZeneca drugs as monotherapy or in combination at any disease stage. The study tracks patients independently of treatment decisions made by their doctors. Each cohort represents a different stage of NSCLC, allowing specific assessment for each group. Participants will be followed to collect real-world data on outcomes such as disease-free survival, event-free survival, treatment failure times, response rates, progression-free survival, and overall survival over periods ranging from 3 to 5 years. Researchers will analyze treatment responses, recurrence-free survival, and treatment discontinuation times among other measures. The study involves no intervention from researchers on treatment plans and focuses on monitoring outcomes in routine clinical practice.